"Skin rashes" and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management

Immune checkpoint inhibitors have shown efficacy in the treatment of different cancers by stimulating the antitumoral activity of the patient's immune system, representing a major breakthrough in the field of cancer therapy. Monoclonal antibodies including anti-cytotoxic T-lymphocyte-associated...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Human vaccines & immunotherapeutics Jg. 18; H. 3; S. 1889449
Hauptverfasser:	Sollena, Pietro, Cappilli, Simone, Federico, Francesco, Schinzari, Giovanni, Tortora, Giampaolo, Peris, Ketty
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Taylor & Francis 31.05.2022 Taylor & Francis Group
Schlagworte:	Advanced melanoma Antibodies, Monoclonal - adverse effects Antineoplastic Agents, Immunological - adverse effects CTLA-4 Antigen - antagonists & inhibitors CTLA-4 inhibitors cutaneous adverse events Exanthema - chemically induced Humans immune checkpoint inhibitors Immunotherapy - adverse effects Melanoma - drug therapy Melanoma – Mini-Review PD-1 inhibitors skin rash skin rash cutaneous adverse events PD-1 inhibitors immune checkpoint inhibitors Advanced melanoma CTLA-4 inhibitors
ISSN:	2164-5515, 2164-554X, 2164-554X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!